Development and validation of SCOPE score: A clinical score to predict COVID-19 pneumonia progression to severe respiratory failure

Cell Rep Med. 2022 Feb 25;3(3):100560. doi: 10.1016/j.xcrm.2022.100560. eCollection 2022 Mar 15.


Most patients infected with SARS-CoV-2 (COVID-19) experience mild, non-specific symptoms, but many develop severe symptoms associated with an excessive inflammatory response. Elevated plasma concentrations of soluble urokinase plasminogen activator receptor (suPAR) provide early warning of progression to severe respiratory failure (SRF) or death, but access to suPAR testing may be limited. The Severe COvid Prediction Estimate (SCOPE) score, derived from circulating concentrations of C-reactive protein, D- dimers, interleukin-6, and ferritin among patients not receiving non-invasive or invasive mechanical ventilation during the SAVE-MORE study, offers predictive accuracy for progression to SRF or death within 14 days comparable to that of a suPAR concentration of ≥6 ng/mL (area under receiver operator characteristic curve 0.81 for both). The SCOPE score is validated in two similar independent cohorts. A SCOPE score of 6 or more is an alternative to suPAR for predicting progression to SRF or death within 14 days of hospital admission for pneumonia, and it can be used to guide treatment decisions.

Keywords: C-reactive protein; COVID-19; D dimers; SARS-CoV-2; biomarkers; disease progression; ferritin; interleukin-6; soluble urokinase plasminogen activator receptor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • COVID-19* / diagnosis
  • Humans
  • Prognosis
  • Receptors, Urokinase Plasminogen Activator
  • Respiratory Insufficiency* / diagnosis
  • SARS-CoV-2


  • Biomarkers
  • Receptors, Urokinase Plasminogen Activator